Dr. Saranraj Kamaraj’s Post

TL;DR: 1st levothyroxine MIPD for use in primary care suggests higher accuracy than conventional age or weight-based methods (using retrospective data + clinical simluation trials) American Society for Clinical Pharmacology & Therapeutics: ➡ https://bit.ly/3Vurpgu | #ModelInformedPrecisionDosing #MIPD #PresicionMedicine #PrecisionDosing #Levothyroxine

Despite PGx testing being instituted into standard clinical workflows, genotype-guided recommendations are not being adopted by all prescribers during treatment. To change standard of care, professional society clinical practice guidelines would need to endorse these recommendations; however, there has been hesitancy to do so without prospective randomized controlled trial data. How do we demonstrate evidence for implementation in cases where randomized controlled trials are not practical? Published in Clinical Pharmacology & Therapeutics. https://hubs.ly/Q02QDLqb0 | #PrecisionMedicine #PGx #Pharmacogenomics #Pharmacology Indiana University School of Medicine

💊 Dexamethasone and Direct Oral Anticoagulants: What Impact? 🤔 Dexamethasone is a key treatment for severe forms of COVID-19, but it could theoretically interact with direct oral anticoagulants such as apixaban and rivaroxaban, increasing the risk of thrombosis. 🚨 Our PBPK-based simulation published in the official journal of the American Society for Clinical Pharmacology & Therapeutics: Clinical Pharmacology & Therapeutics have shown that dexamethasone has possibly a limited impact on these medications in a worst-case scenario. 🤓✅ The results also suggest that prednisone could be an interesting alternative, with fewer induction effects. 🤝 Therefore, this study adding to the limited available literature suggest that the combined use of these anticoagulants and dexamethasone could be feasible in certain cases, particularly for patients at low thrombotic risk. 🩺⚕️ Thanks to all the coauthors Caroline Samer Youssef Daali Kenza Abouir, PhD Frédéric Gaspar ASCPT Journal Family https://lnkd.in/eMWStXfY #COVID19 #Pharmacology #Anticoagulants #Dexamethasone #Medicine

Recently, pharmacology, toxicity and human research were published in multiple peer-reviewed journals. GlucoMedix was compared to Glibenclamide, Enalapril and Atorvastatin producing similar pharmacological effects. Acute and subacute oral toxicity was performed with no toxicity, abnormal clinical chemistry or haematological effects observed. In a six patient case series, GlucoMedix reduced glucose levels and the need for pharmaceuticals in patients with type 2 diabetes. Although multiple prescription drugs are well known for the treatment of individual comorbidities of metabolic syndrome, no drug monotherapy concurrently treats all three comorbidities. Hear more about these patient case studies with Armin Schwarzbach at the NutraMedix workshop taking place at the Integrative & Personalised Medicine congress. Register for just £25 per day: https://lnkd.in/eG-WbvBn (link in bio) #ipmcongress #integrativemedicine #lifestylemedicine #functionalmedicine #wholepersonhealth #metabolichealth #metabolicsyndrome

In Med Sparkle's pharmacology crash course, I delved into the complex realm of diabetes and its management through medications. I gained insights into the pathophysiology of diabetes, including the role of insulin and glucose metabolism. They explored various classes of diabetes drugs, such as insulin analogs, oral hypoglycemic agents, and GLP-1 receptor agonists, understanding their mechanisms of action and clinical applications. Through comprehensive discussions on dosage regimens, monitoring parameters, and patient education, I acquired essential skills for effective diabetes management.

This recent study investigated which factors are associated with receiving pharmacogenetically targeted drugs, and estimated cost-effects of untargeted pre-emptive pharmacogenetic panel testing with a cost–benefit model. Published in Clinical Pharmacology & Therapeutics. https://hubs.ly/Q02ZBjHb0 | #Pharmacogenetics #PrecisionMedicine #CostBenefitModel Kaisa Litonius University of Helsinki Noora Kulla Turun yliopisto - University of Turku American Society for Clinical Pharmacology & Therapeutics

Psychopharmacological treatment in patients planned for hip or knee replacement New study in Basic & Clinical Pharmacology & Toxicology aimed to describe the psychopharmacological treatments in hip and knee replacement patients in terms of type, dose, duration, indication, and initiating physician. It found that antidepressants were the most common psychopharmacological treatments. Most antidepressants were initiated by general practitioners and were primarily serotonin reuptake inhibitors in moderate doses lasting more than 1 year. This suggests that temporary perioperative discontinuation of serotonin reuptake inhibitors may be feasible in hip and knee replacement patients. Study conducted by Simon Kornvig, Henrik Kehlet, Christoffer Jørgensen, Anders Fink-Jensen, Poul Videbech, Martin Lindberg-Larsen, Kirill Gromov, Mathias Bæk Rasmussen, Manuel Josef Bieder and Claus Varnum. Read the full paper here: https://lnkd.in/dhSUfSTP

New webinar available on-demand: Clinical Pharmacology & Model-Informed Drug Development (MIDD) Insights for Targeted Radiation Therapies (TRT). Hear from our team of experts to learn how MIDD can address the unique considerations and challenges in TRT development! Watch on-demand: https://ow.ly/zKZl50STpPz #ClinicalPharmacology #Pharmacometrics #QuantitativeSystemsPharmacology #Radiopharmaceuticals #TargetedRadiationTherapies #DrugDevelopment

Neat visual abstract of our recent publication entitled “Clinical pharmacology consideration for first-in-human clinical trials for enzyme replacement therapy”!  read here: https://lnkd.in/eapqSHRS

ONCOLOGY: TARGETED COVALENT INHIBITORS (TCIs) vs. REVERSIBLE INHIBITORS A Comparative Clinical Pharmacology Analysis of FDA - Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology Targeted covalent inhibitors (TCIs) are an emerging class of anticancer therapeutics. TCIs are designed to selectively engage their targeted proteins via covalent warheads. From the drug development standpoint, the covalent inhibition mechanism is anticipated to elicit the following theoretical benefits: (i) an extended duration of therapeutic action that is determined by the target protein turnover rate and not necessarily by drug half-life, (ii) a lower therapeutic dose owing to greater pharmacological potency, (iii) lower risk of off-target binding and associated adverse events, and (iv) reduced drug–drug interaction (DDI) liability due to high selectivity and low dose. This review compared the clinical pharmacology attributes of FDA-approved oncology TCIs within the last 10years against their reversible inhibitor (RI) counterparts. The overall clinical pharmacology comparison of TCI vs. RI surveyed in this paper suggested that at least two of the four forecasted clinical benefits were achieved by TCIs. #oncology #TargetedCovalentInhibitors #ReversibleInhibitors #FDA